.jpg)
.png)
Abstract: The first efforts to uncover the causes of cardiovascular disease focused on the behavioral, now called lifestyle habits of populations. Diet, exercise, and smoking were recognized as important issues with strong relationships in community-based observational studies such as the Seven Countries study, the Framingham Heart Study, and the Western Electric Study in Chicago.
all
Following a June 2015 recommendation by the U.S Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee, the FDA has approved alirocumab for patients on maximally tolerated statin therapy with heterozygous familial hypercholesterolemia (HeFH) or with clinical atherosclerotic cardiovascular disease such as heart attacks or strokes, who require additional lowering of LDL cholesterol. Alirocumab is produced by Sanofi and Regeneron, and known by the brand name Praluent.
Dr. Patrick McBride, Associate Dean for Students at University of Wisconsin School of Medicine and Public Health, was recently honored with the Distinguished Achievement Award at the National Lipid Association’s 2015 Annual Sessions.